Correlation
The correlation between VRNA and ARCC is 0.51, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
VRNA vs. ARCC
Compare and contrast key facts about Verona Pharma plc (VRNA) and Ares Capital Corporation (ARCC).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: VRNA or ARCC.
Performance
VRNA vs. ARCC - Performance Comparison
Loading data...
Key characteristics
VRNA:
10.30
ARCC:
0.62
VRNA:
6.33
ARCC:
1.01
VRNA:
1.78
ARCC:
1.15
VRNA:
9.87
ARCC:
0.70
VRNA:
89.98
ARCC:
2.69
VRNA:
6.15%
ARCC:
4.89%
VRNA:
60.04%
ARCC:
20.81%
VRNA:
-89.71%
ARCC:
-79.40%
VRNA:
0.00%
ARCC:
-5.27%
Fundamentals
VRNA:
$6.59B
ARCC:
$15.27B
VRNA:
-$2.00
ARCC:
$2.04
VRNA:
0.00
ARCC:
3.95
VRNA:
55.55
ARCC:
5.05
VRNA:
29.11
ARCC:
1.12
VRNA:
$118.54M
ARCC:
$2.13B
VRNA:
$112.28M
ARCC:
$2.04B
VRNA:
-$176.07M
ARCC:
$1.83B
Returns By Period
In the year-to-date period, VRNA achieves a 74.85% return, which is significantly higher than ARCC's 3.04% return.
VRNA
74.85%
12.67%
104.90%
607.32%
161.71%
76.36%
N/A
ARCC
3.04%
6.73%
4.09%
12.74%
15.05%
19.17%
13.16%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
VRNA vs. ARCC — Risk-Adjusted Performance Rank
VRNA
ARCC
VRNA vs. ARCC - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Ares Capital Corporation (ARCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
VRNA vs. ARCC - Dividend Comparison
VRNA has not paid dividends to shareholders, while ARCC's dividend yield for the trailing twelve months is around 8.71%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARCC Ares Capital Corporation | 8.71% | 8.77% | 9.59% | 10.12% | 7.65% | 9.47% | 9.01% | 9.88% | 9.67% | 9.22% | 11.02% | 10.06% |
Drawdowns
VRNA vs. ARCC - Drawdown Comparison
The maximum VRNA drawdown since its inception was -89.71%, which is greater than ARCC's maximum drawdown of -79.40%. Use the drawdown chart below to compare losses from any high point for VRNA and ARCC.
Loading data...
Volatility
VRNA vs. ARCC - Volatility Comparison
Verona Pharma plc (VRNA) has a higher volatility of 13.72% compared to Ares Capital Corporation (ARCC) at 5.18%. This indicates that VRNA's price experiences larger fluctuations and is considered to be riskier than ARCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
VRNA vs. ARCC - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and Ares Capital Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRNA vs. ARCC - Profitability Comparison
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Verona Pharma plc reported a gross profit of 72.85M and revenue of 76.26M. Therefore, the gross margin over that period was 95.5%.
ARCC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Ares Capital Corporation reported a gross profit of 505.00M and revenue of 599.00M. Therefore, the gross margin over that period was 84.3%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Verona Pharma plc reported an operating income of -10.32M and revenue of 76.26M, resulting in an operating margin of -13.5%.
ARCC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Ares Capital Corporation reported an operating income of 434.00M and revenue of 599.00M, resulting in an operating margin of 72.5%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Verona Pharma plc reported a net income of -16.32M and revenue of 76.26M, resulting in a net margin of -21.4%.
ARCC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Ares Capital Corporation reported a net income of 365.00M and revenue of 599.00M, resulting in a net margin of 60.9%.